Sign Up Now!
To sign up for our newsletter or print publications, please enter your contact information below.
First Name *
Last Name *
Email Address (Verify) *
We will request your mailing address on the next page.
We will request your mailing address on the next page.

FORTE Trial: Analysis of Survival in Newly Diagnosed, Transplant-Eligible Patients with Multiple Myeloma

Conference Correspondent  - ASH Highlights

Induction/consolidation is effective for patients with newly diagnosed multiple myeloma (NDMM) who are eligible for melphalan 200 mg/m2 + autologous stem-cell transplant (MEL200-ASCT), with high response rates seen with carfilzomib (K) + lenalidomide (R) + dexamethasone (KRd) or cyclophosphamide + dexamethasone (KCd). The primary aims of this analysis were to assess the progression-free survival (PFS) of KRd induction-ASCT-KRd consolidation (KRd_ASCT) versus 12 cycles of KRd (KRd12) versus KCd induction-ASCT-KCd consolidation (KCd_ASCT), and the PFS of KR versus lenalidomide monotherapy maintenance.

Patients aged ≤65 years with NDMM were randomized to KRd_ASCT for 4 28-day cycles with KRd induction (intravenous [IV] carfilzomib 20/36 mg/m2 on days 1, 2, 8, 9, 15, and 16; lenalidomide 25 mg on days 1-21; and dexamethasone 20 mg on days 1, 2, 8, 9, 15, and 16) followed by MEL200-ASCT and 4 KRd consolidation cycles; KRd12; KCd_ASCT for 4 28-day induction cycles with KCd (IV carfilzomib 20/36 mg/m2 on days 1, 2, 8, 9, 15, and 16; cyclophosphamide 300 mg/m2 on days 1, 8, and 15; and dexamethasone 20 mg on days 1, 2, 8, 9, 15, and 16) followed by MEL200-ASCT and 4 KCd consolidation cycles. Patients were then randomized to KR (carfilzomib 36 mg/m2 on days 1, 2, 15, and 16, subsequently amended to 70 mg/m2 on days 1 and 15 for up to 2 years; + lenalidomide 10 mg on days 1-21 every 28 days until progression) or lenalidomide alone (10 mg on days 1-21 every 28 days until progression) for maintenance. Minimal residual disease (MRD) analysis was conducted in patients with very good partial response or better before maintenance, and then every 6 months.

Patients with NDMM were randomized 158, 157, and 159 to KRd_ASCT, KRd12, and KCd_ASCT, respectively. Median PFS after a median follow-up of 45 months was significantly longer for KRd_ASCT versus KCd_ASCT (hazard ratio [HR], 0.53; P <.001), significantly longer for KRd_ASCT versus KRd12 (HR, 0.64; P = .023) and not significantly different for KRd12 versus KCd_ASCT (HR, 0.82; P =.262). Patients (n = 356) underwent a second randomization (R2) for maintenance, 178 to either KR or lenalidomide. Premaintenance responses were well matched, with ~60% of patients achieving complete response or better and ~65% being MRD negative. Significantly more patients who were MRD positive at randomization transitioned to MRD negative with KR versus lenalidomide after a median follow-up of 31 months (46% vs 32%; P = .04). The PFS was significantly longer after R2 in the KR arm versus the lenalidomide-alone arm (81% vs 68%; P = .026). The overall survival was 93% with KR and 90% with lenalidomide (P = .249).

A similar proportion of patients experienced ≥1 grade 3/4 hematologic adverse events (AEs)/serious AEs (SAEs) in both arms (22% [KR] vs 23% [lenalidomide]), with 18% and 21% of patients experiencing neutropenia with KR and lenalidomide, respectively, and 3% of patients in both arms experiencing thrombocytopenia. More patients experienced ≥1 grade 3/4 nonhematologic AEs/SAEs with KR (27%) versus lenalidomide (15%; P = .012), with infections being the most frequent (4% [KR] vs 7% [lenalidomide]). A second primary malignancy was observed in 4 patients receiving KR (n = 1 for the following: breast, thyroid, myelodysplastic syndrome, nonmelanoma skin cancer) versus 1 patient receiving lenalidomide (acute lymphoblastic leukemia). Dose reductions of lenalidomide occurred in 23% and 29% of patients in the KR and lenalidomide arms, respectively, and dose reductions of carfilzomib occurred in 20% of patients. The discontinuation rates resulting from toxicities were 10% versus 9% with KR and lenalidomide, respectively.

PFS was significantly longer with KRd_ASCT versus either KRd12 or KCd_ASCT in transplant-eligible patients with NDMM. A significant improvement in PFS was also observed upon maintenance with KR versus lenalidomide.


Reference

Abstract 141. ASH 2020. December 5, 2020. Survival Analysis of Newly Diagnosed Transplant-Eligible Multiple Myeloma Patients in the Randomized FORTE Trial.

Related Items
Oral Vodobatinib Elicits Durable Responses in Heavily Pretreated Patients with Chronic Myeloid Leukemia
JHOP - February 2021 Vol 11, No 1 published on February 22, 2021 in ASH Highlights, Leukemia, Novel Pharmaceuticals
Momelotinib, a Novel JAK Inhibitor, Makes Inroads in Intermediate- or High-Risk Myelofibrosis
JHOP - February 2021 Vol 11, No 1 published on February 22, 2021 in ASH Highlights, Myelofibrosis, Novel Pharmaceuticals
ZUMA-12: Axicabtagene Ciloleucel Shows Substantial Benefit in High-Risk Large B-Cell Lymphoma
JHOP - February 2021 Vol 11, No 1 published on February 22, 2021 in ASH Highlights, CAR T-Cell Therapy, Lymphoma
Step-Up Glofitamab Dosing Induces High Response Rates in Relapsed or Refractory Non-Hodgkin Lymphoma
JHOP - February 2021 Vol 11, No 1 published on February 22, 2021 in ASH Highlights, Clinical Trials, Lymphoma
Ruxolitinib in Graft-versus-Host Disease: Practice-Changing Results
JHOP - February 2021 Vol 11, No 1 published on February 22, 2021 in ASH Highlights, Graft-versus-Host-Disease
Pevonedistat plus Azacitidine Improves Outcomes versus Azacitidine Monotherapy in High-Risk MDS
JHOP - February 2021 Vol 11, No 1 published on February 22, 2021 in ASH Highlights, Myelodysplastic Syndromes
A Phase 2 Study of Isatuximab for Patients with Previously Treated AL Amyloidosis
Conference Correspondent  published on December 9, 2020 in ASH Highlights
VRD Consolidation Followed by Lenalidomide Maintenance versus Maintenance Alone in Transplant-Eligible Patients with NDMM
Conference Correspondent  published on December 9, 2020 in ASH Highlights
A Dose-Finding Study of Belantamab Mafodotin in Combination with Pomalidomide and Dexamethasone for RRMM
Conference Correspondent  published on December 9, 2020 in ASH Highlights
Phase 2 GRIFFIN Study Update: Daratumumab + Lenalidomide, Bortezomib, and Dexamethasone in Transplant-Eligible NDMM
Conference Correspondent  published on December 9, 2020 in ASH Highlights
Copyright © Green Hill Healthcare Communications, LLC. All rights reserved.